MEKTOVI
Drug
PFIZER INC.
Total Payments
$29.8M
Transactions
673
Doctors
128
Companies
4
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $3.4M | 34 | 17 |
| 2023 | $7.1M | 111 | 44 |
| 2022 | $7.9M | 161 | 53 |
| 2021 | $5.2M | 167 | 6 |
| 2020 | $6.2M | 197 | 26 |
| 2019 | $33.69 | 3 | 3 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $29.7M | 552 | 99.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $33,710 | 11 | 0.1% |
| Honoraria | $31,450 | 8 | 0.1% |
| Food and Beverage | $5,826 | 99 | 0.0% |
| Travel and Lodging | $713.54 | 3 | 0.0% |
Payments by Type
Research
$29.7M
552 transactions
General
$71,700
121 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| INVESTIGATION OF TOFACITINIB TO MITIGATE THE IMPACT OF COVID19 ITOMIC IN MODERATE SARSCOV2 MODERATE ITOMIC | PFIZER INC. | $4.3M | 0 |
| BINIMETINIB IN CHILDREN AND ADULTS WITH NF1 ASSOCIATED PLEXIFORM NEUROFIBROMAS | PFIZER INC. | $3.6M | 0 |
| EAY191N2PHASE 2 TRIAL OF FULVESTRANT AND BINIMETINIB IN PATIENTS WITH HORMONE RECEPTORPOSITIVE METASTATIC BREAST CANCER WITH A FRAMESHIFT OR NONSENSE MUTATION OR GENOMIC DELETION IN NF1 | PFIZER INC. | $2.8M | 0 |
| MEK162 BINIMETINIB IN COMBINATION WITH IMATINIB IN PATIENTS WITH ADVANCED GIST | PFIZER INC. | $2.1M | 0 |
| EAY191A6FOLFOX IN COMBINATION WITH BINIMETINIB AS 2ND LINE THERAPY FOR PATIENTS WITH ADVANCED BILIARY TRACT CANCERS WITH MAPK PATHWAY ALTERATIONSEAY191A6 | PFIZER INC. | $1.8M | 0 |
| IMMUNOTHERAPY COMBINATION STRATEGIES TO TREAT TRIPLE NEGATIVE BREAST CANCER TNBCA MULTICENTER MULTIARM TRANSLATIONAL BREAST CANCER RESEARCH CONSORTIUM TBCRC STUDY | PFIZER INC. | $1.8M | 0 |
| THE MILO STUDY MEK INHIBITOR IN LOWGRADE SEROUS OVARIAN CANCER A MULTINATIONAL RANDOMIZED OPENLABEL PHASE 3 STUDY OF MEK162 VS PHYSICIANS CHOICE CHEMOTHERAPY IN PATIENTS WITH RECURRENT OR PERSISTENT LOWGRADE SEROUS CARCINOMAS OF THE OVARY FALLOPIAN TUBE OR PRIMARY PERITONEUM | ARRAY BIOPHARMA INC | $1.7M | 4 |
| A PHASE II STUDY OF BINIMETINIB IN COMBINATION WITH ENCORAFENIB IN ADULTS WITH RECURRENT BRAF V600MUTATED HIGHGRADE ASTROCYTOMA OR OTHER PRIMARY BRAIN TUMORWI256081 | PFIZER INC. | $1.4M | 0 |
| BINIMETINIB PEMBROLIZUMAB BEVACIZUMAB IN PATIENTS WITH MSS MCRC | PFIZER INC. | $1.4M | 0 |
| WI2115413 IMMUNOTHERAPY COMBINATION STRATEGIES TO TREAT TRIPLE NEGATIVE BREAST CANCER TNBCA MULTICENTER MULTIARM TRANSLATIONAL BREAST CANCER RESEARCH CONSORTIUM TBCRC STUDY | PFIZER INC. | $1.3M | 0 |
| BINIMETINIB PLUS HYDROXYCHLOROQUINE IN KRAS MUTANT PANCREATIC CANCER | PFIZER INC. | $1.1M | 0 |
| A 2PART PHASE III RANDOMIZED OPEN LABEL MULTICENTER STUDY OF LGX818 PLUS MEK162 VERSUS VEMURAFENIB AND LGX818 MONOTHERAPY IN PATIENTS WITH UNRESECTABLE OR METASTATIC BRAF V600 MUTANT MELANOMA | ARRAY BIOPHARMA INC | $962,424 | 0 |
| A PHASE II STUDY OF BINIMETINIB IN COMBINATION WITH IMATINIB IN PATIENTS WITH ADVANCED KIT MUTANT MELANOMA | PFIZER INC. | $871,051 | 0 |
| PHASE 2 STUDY OF THE MEK INHIBITOR MEKTOVI BINIMETINIB FOR THE TREATMENT OF PROGRESSIVERECURRENT PEDIATRIC ADAMANTINOMATOUS CRANIOPHARYNGIOMA | PFIZER INC. | $656,069 | 0 |
| FOLFIRI WITH MEK162 IN PATIENTS WITH ADVANCED KRAS POSITIVE METASTATIC CRC | PFIZER INC. | $460,181 | 0 |
| AN OPENLABEL PHASE 1B2 STUDY OF BINIMETINIB ADMINISTERED IN COMBINATION WITH NIVOLUMAB OR NIVOLUMAB PLUS IPILIMUMAB IN PATIENTS WITH PREVIOUSLY TREATED MICROSATELLITESTABLE MSS METASTATIC COLORECTAL CANCER WITH RAS MUTATION | ARRAY BIOPHARMA INC | $447,525 | 0 |
| A PHASE II STUDY OF BINIMETINIB PLUS BELINOSTAT FOR SUBJECTS WITH METASTATIC UVEAL MELANOMA | PFIZER INC. | $369,110 | 0 |
| THE MILO STUDY MEK INHIBITOR IN LOWGRADE SEROUS OVARIAN CANCER A MULTINATIONAL RANDOMIZED OPENLABEL PHASE 3 STUDY OF MEK162 VS PHYSICIANS CHOICE CHEMOTHERAPY IN PATIENTS WITH RECURRENT OR PERSISTENT LOWGRADE SEROUS CARCINOMAS OF THE OVARY FALLOPIAN TUBE OR PRIMARY PERITONEUM | PFIZER INC. | $330,845 | 0 |
| A PHASE II STUDY OF BINIMETINIB IN COMBINATION WITH IMATINIB IN PATIENTS WITH ADVANCED KIT MUTANT MELANOMA | ARRAY BIOPHARMA INC | $315,040 | 0 |
| A PHASE I STUDY OF BRIGATINIB WITH BINIMETINIB IN ADVANCED ALK OR ROS1REARRANGED NONSMALL CELL LUNG CANCER NSCLC | PFIZER INC. | $314,903 | 0 |
Ad
Manufacturing Companies
- PFIZER INC. $25.3M
- ARRAY BIOPHARMA INC $4.3M
- Deciphera Pharmaceuticals Inc. $94,400
- Pfizer Inc. $59,795
Product Information
- Type Drug
- Total Payments $29.8M
- Total Doctors 128
- Transactions 673
About MEKTOVI
MEKTOVI is a drug associated with $29.8M in payments to 128 healthcare providers, recorded across 673 transactions in the CMS Open Payments database. The primary manufacturer is PFIZER INC..
Payment data is available from 2019 to 2024. In 2024, $3.4M was paid across 34 transactions to 17 doctors.
The most common payment nature for MEKTOVI is "Unspecified" ($29.7M, 99.8% of total).
MEKTOVI is associated with 20 research studies, including "INVESTIGATION OF TOFACITINIB TO MITIGATE THE IMPACT OF COVID19 ITOMIC IN MODERATE SARSCOV2 MODERATE ITOMIC" ($4.3M).